LONSUBIQ
Live / Registered — Registered (as of 14 Nov 2023)
What this means for you
Registered since 14 Nov 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97152371
- Registration number
- 7215876
- Mark type
- Stylized text
- Filed
- 02 Dec 2021
- Published for opposition
- 29 Aug 2023
- Registered
- 14 Nov 2023
- Attorney of record
- Scott D. Woldow
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome (ARDS); pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases (ILD); Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema (HAE)
Owner
- CSL Behring GmbH, Marburg, DE
- CSL Behring GmbH, Marburg, DE
- CSL Behring GmbH, Marburg, DE
Prosecution history
- 14 Nov 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 14 Nov 2023 — REGISTERED-PRINCIPAL REGISTER
- 29 Aug 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 29 Aug 2023 — PUBLISHED FOR OPPOSITION
- 09 Aug 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 27 Jul 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 27 Jun 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 26 Jun 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 26 Jun 2023 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
- 15 Jun 2023 — NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
- 15 Jun 2023 — INQUIRY TO SUSPENSION E-MAILED
- 15 Jun 2023 — SUSPENSION INQUIRY WRITTEN
- 15 Jun 2023 — SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
- 01 Dec 2022 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 01 Dec 2022 — LETTER OF SUSPENSION E-MAILED